These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 38246416)
1. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software. Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Duncan DP; Taylor JE; Brown DB J Vasc Interv Radiol; 2024 May; 35(5):689-698.e3. PubMed ID: 38246416 [TBL] [Abstract][Full Text] [Related]
2. Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors after Yttrium-90 Resin Microsphere Radioembolization. Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Taylor JE; Brown DB J Vasc Interv Radiol; 2024 May; 35(5):699-708. PubMed ID: 37871833 [TBL] [Abstract][Full Text] [Related]
3. Predictive Partition Dosimetry and Outcomes after Yttrium-90 Resin Microsphere Radioembolization of Colorectal Cancer Metastatic to the Liver: A Retrospective Analysis. Doyle PW; Workman CS; Shah N; McGonigle TW; Grice JV; Huang S; Borgmann AJ; Baker JC; Guys NP; Taylor JE; Brown DB J Vasc Interv Radiol; 2023 Dec; 34(12):2138-2146. PubMed ID: 37640105 [TBL] [Abstract][Full Text] [Related]
4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133 [TBL] [Abstract][Full Text] [Related]
5. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346 [TBL] [Abstract][Full Text] [Related]
6. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745 [TBL] [Abstract][Full Text] [Related]
7. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503 [TBL] [Abstract][Full Text] [Related]
8. Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT. Villalobos A; Cheng B; Wagstaff W; Sethi I; Bercu Z; Schuster DM; Brandon DC; Galt J; Kokabi N J Vasc Interv Radiol; 2021 May; 32(5):752-760. PubMed ID: 33642158 [TBL] [Abstract][Full Text] [Related]
9. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT. Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827 [TBL] [Abstract][Full Text] [Related]
10. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma. Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137 [TBL] [Abstract][Full Text] [Related]
12. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962 [TBL] [Abstract][Full Text] [Related]
13. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V; Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828 [TBL] [Abstract][Full Text] [Related]
14. The Utility of Unilobar Technetium-99m Macroaggregated Albumin to Predict Pulmonary Toxicity In Bilobar Hepatocellular Carcinoma prior to Yttrium-90 Radioembolization. Kallini JR; Gabr A; Kulik L; Salem R; Lewandowski RJ J Vasc Interv Radiol; 2016 Sep; 27(9):1453-1456. PubMed ID: 27566430 [No Abstract] [Full Text] [Related]
15. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe. Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039 [TBL] [Abstract][Full Text] [Related]
16. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387 [TBL] [Abstract][Full Text] [Related]
17. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT. Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581 [TBL] [Abstract][Full Text] [Related]
18. Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing Noipinit N; Sukprakun C; Siricharoen P; Khamwan K Ann Nucl Med; 2024 Mar; 38(3):210-218. PubMed ID: 38142421 [TBL] [Abstract][Full Text] [Related]
19. Measurement of the Tumor-to-Normal Ratio for Radioembolization of Hepatocellular Carcinoma: A Prospective Study Comparing 2-Dimensional Perfusion Angiography, Technetium-99m Macroaggregated Albumin, and Yttrium-90 SPECT/CT. Brunson CP; McGregor HJ; Hennemeyer CT; Patel MV; Woodhead GJ; Young SJ J Vasc Interv Radiol; 2024 Jan; 35(1):94-101. PubMed ID: 37783268 [TBL] [Abstract][Full Text] [Related]
20. Imageable Radioembolization Microspheres for Treatment of Unresectable Hepatocellular Carcinoma: Interim Results from a First-in-Human Trial. Abraham RJ; Arepally A; Liu D; Lewandowski R; Kappadath SC; Verma A; Dobrowski D; Holden A J Vasc Interv Radiol; 2024 Oct; 35(10):1464-1473.e1. PubMed ID: 38944236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]